BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26637914)

  • 1. Capecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective Study.
    Abrams MJ; Huber KE; Knisely JP; Chang BW; Russo SM; Saif MW
    Anticancer Res; 2015 Dec; 35(12):6901-7. PubMed ID: 26637914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer.
    Chadha AS; Skinner HD; Gunther JR; Munsell MF; Das P; Minsky BD; Delclos ME; Chatterjee D; Wang H; Clemons M; George G; Singh PK; Katz MH; Fleming JB; Javle MM; Wolff RA; Varadhachary GR; Crane CH; Krishnan S
    PLoS One; 2016; 11(6):e0156910. PubMed ID: 27336466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
    Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
    Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.
    Crane CH; Ellis LM; Abbruzzese JL; Amos C; Xiong HQ; Ho L; Evans DB; Tamm EP; Ng C; Pisters PW; Charnsangavej C; Delclos ME; O'Reilly M; Lee JE; Wolff RA
    J Clin Oncol; 2006 Mar; 24(7):1145-51. PubMed ID: 16505434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum.
    Saha A; Ghosh SK; Roy C; Saha ML; Choudhury KB; Chatterjee K
    J Cancer Res Ther; 2015; 11(1):88-93. PubMed ID: 25879343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
    Keene KS; Rich TA; Penberthy DR; Shepard RC; Adams R; Jones RS
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):97-103. PubMed ID: 15850908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer.
    Morganti AG; Falconi M; van Stiphout RG; Mattiucci GC; Alfieri S; Calvo FA; Dubois JB; Fastner G; Herman JM; Maidment BW; Miller RC; Regine WF; Reni M; Sharma NK; Ippolito E; Valentini V
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):911-7. PubMed ID: 25220717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
    Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
    Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer.
    Kim JC; Kim TW; Kim JH; Yu CS; Kim HC; Chang HM; Ryu MH; Park JH; Ahn SD; Lee SW; Shin SS; Kim JS; Choi EK
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):346-53. PubMed ID: 15913913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemoradiotherapy for high-risk pancreatic cancer.
    Wang ML; Foo KF
    Singapore Med J; 2009 Jan; 50(1):43-8. PubMed ID: 19224083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.
    Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-operative chemoradiotherapy using capecitabine and cetuximab followed by definitive surgery in patients with operable rectal cancer.
    Bazarbashi S; Omar A; Aljubran A; Alzahrani A; Alsanea N; Abduljabbar A; Alhomoud S; Ashari L; Balaraj K; Soudy H; Neimatallah M; Fagih M
    Hematol Oncol Stem Cell Ther; 2016 Dec; 9(4):147-153. PubMed ID: 27613373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective Analysis of Capecitabine and Radiation Therapy in the Treatment of Pancreatic Cancer.
    Saif MW; Joseph M; Tang S; Vickers S; Plants B; Russo S
    J Appl Res; 2004; 4(4):635-646. PubMed ID: 19081804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma.
    Leng J; Akthar AS; Szmulewitz RZ; O'Donnell PH; Sweis RF; Pitroda SP; Smith N; Steinberg GD; Liauw SL
    Clin Genitourin Cancer; 2019 Feb; 17(1):e12-e18. PubMed ID: 30392939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
    Saif MW; Eloubeidi MA; Russo S; Steg A; Thornton J; Fiveash J; Carpenter M; Blanquicett C; Diasio RB; Johnson MR
    J Clin Oncol; 2005 Dec; 23(34):8679-87. PubMed ID: 16314628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
    Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
    Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.